Science moves fast. New markers, methods, and data analysis, clinical trial updates, advances in techniques, and on and on. With so much to keep track of, it’s hard to focus on what can make a difference to your research. Points of Vue is a space where we cover the latest news and updates on topics that are near and dear to our hearts at Ultivue.
November 15, 2022
EVIDENT and Ultivue Collaborate to Advance Multiplex Slide Imaging and Spatial Analysis in Translational Research
Combining Ultivue’s mIF assays with the Olympus SLIDEVIEW™ VS200 research slide scanner provides a convenient, fast tool for whole slide mIF imaging in translational studies for researchers in academia, biotech, pharma and contract research organizations in the Americas. The collaboration builds on their existing partnership to meet the scientific community’s increasing need for fluorescent multiplexing.
November 3, 2022
Ultivue and ZEISS to Co-Market Complete Solution for Spatial Phenomics
Ultivue VUE panels for multiplex immune-labeling offer endless options for researchers to characterize complex, tissue immune biology. With unprecedented signal-to-noise and options for pre-designed panels or customized panels, Ultivue solutions are designed to label tissues for in-depth data mining for spatial phenomics. The ZEISS Axioscan automated whole slide imager offers unparalleled fluorescence imaging and resolution
September 29, 2022
Ultivue and ngTMA® Announce Collaborative Agreement to Provide Multiplex and Spatial Analysis for Clinical Research
Ultivue develops unique solutions for use in mIF applications, imaging, and spatial phenomics. Its proprietary InSituPlex® technology enabling improved signal to noise data is designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in tissue samples combines the power of computational pathology & spatial biology to guide
April 7, 2022
Ultivue Announces Co-Marketing and Co-Development Collaboration with Paige for AI-Powered Biomarker Imaging Solutions for Precision Medicine
Collaborative efforts will initially focus on the development of AI to enable improved understanding of the tumor microenvironment and support the interpretation of Ultivue’s novel multiplex immunofluorescence (mIF) immuno-oncology biomarker panels. The Paige portfolio includes the Paige Platform, a comprehensive imaging solution composed of the FDA-cleared and CE-marked FullFocus™, an intuitive and responsive viewer for
April 6, 2022
Ultivue Announces Multiple Events for Multiplex Immunofluorescence and Image Analysis Technology in Immuno-Oncology Research at AACR 2022
Accepted abstracts during the AACR conference will feature new data from a streamlined pre-optimized protocol enabling mIF staining on mouse tissue for an improved workflow to investigate T-cell infiltration and additional analysis of the tumor immune microenvironment (TiME) to address the mechanisms of action of immune-related drugs in preclinical syngeneic or GEMM mouse models. The
March 29, 2022
Keen Eye and Ultivue announce collaborative agreement to propel multiplex and spatial analysis in clinical research
Keen Eye, a leading AI company in digital pathology for clinical research and Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, announce a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and novel AI applications to unlock spatial analysis in clinical research.
March 15, 2022
Ultivue Announces Co-Marketing Agreement with Sirona DX for Multiplexed Tissue Biomarker Solutions for Precision Medicine
Ultivue, Inc. and Sirona Dx, a technical contract research organization (CRO), announced a co-marketing agreement to deliver tissue-based spatial multiplexed immunophenotyping solutions for translational research groups and Biopharma.
March 9, 2022
Unique Spatial AI-Powered Imaging Solutions for Translational Medicine
Ultivue, Inc. and Aignostics GmbH announced a partnership to collaborate on the co-development of AI-powered spatial multiplexed immunophenotype solutions for translational research groups and Biopharma.
February 9, 2022
Ultivue Announces Relocation and Expansion for New Corporate Headquarters
Ultivue, Inc. announced the relocation and expansion of its corporate headquarters to a new office and laboratory facility in Burlington, MA to advance the operations and growth of the company. Avison Young’s Boston office arranged a new 56,000-square-foot lease on behalf of biotechnology company Ultivue at Burlington Biocenter. Ultivue will relocate and triple in size from its previous Cambridge location in the Fall of 2022.
November 4, 2021
Ultivue to Participate in the Stifel 2021 Virtual Healthcare Conference
Ultivue, an industry leader in multiplexing tools for tissue biomarker analysis, will participate in the Stifel 2021 Virtual Healthcare Conference to be held November 15th – 17, 2021. The conference incorporates presentations and innovative panel discussions hosted by senior leadership in the health care industry.
November 2, 2021
Ultivue announces new executive team member
Ultivue announces the addition of Steve Pemberton in the role of SVP Commercial Development, as the company adds to its growing executive team.
August 19, 2021
Ultivue announces two new independent board members
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ultivue announces the addition of two independent board members, Fenel Eloi and Mary Pat Lancelotta, to help strengthen its position as a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation.
August 5, 2021
Ultivue Announces Co-Marketing Agreement with Fluidigm for Biomarker Imaging Solutions for Precision Medicine
Ultivue, Inc. and Fluidigm Corporation (Nasdaq:FLDM) today announced a co-marketing agreement in which the companies will offer customers a comprehensive portfolio of workflow solutions for biomarker discovery and drug development.
April 27, 2021
Ultivue announces $50M financing round
CAMBRIDGE, MA – Ultivue, a leader in advancing precision medicine solutions through a unique approach that combines multiplex biomarker analysis with same slide traditional H&E for tissue phenotyping, today announced the completion of a $50 million Series D round of financing.